Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans-Reference-Cited by-同舟云学术

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

Published:2021-08-19 Issue:2 Volume:379 Page:134-146
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Ayyar Vivaswath S.,Song Dawei,Zheng Songmao,Carpenter Thomas,Heald Donald L.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference61 articles.

1. Impact of serum proteins on the uptake and RNAi activity of GalNAc-conjugated siRNAs;Agarwal;Nucleic Acid Ther,2021

2. Akinc A Sehgal A Brodsky J Qin J Racie T Foster D Milstein S Barros S Hettinger J Panesar S (2012) RNAi-mediated inhibition of a natural anticoagulant for the treatment of hemophilia, in Proceedings of the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, pp A9–A10, Oligonucleotide Therapeutics Society, San Diego, CA.

3. Spartan: a comprehensive tool for understanding uncertainty in simulations of biological systems;Alden;PLOS Comput Biol,2013

4. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids

5. Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development;Journal of Medicinal Chemistry;2024-08-28

2. Whole-Body Physiologically-Based Pharmacokinetic Modeling of GalNAc conjugated siRNAs;2024-08-06

3. Modeling on in vivo disposition and cellular transportation of RNA lipid nanoparticles via quantum mechanics/physiologically-based pharmacokinetic approaches;Acta Pharmaceutica Sinica B;2024-07

4. Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model;Heliyon;2024-06

5. Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies;The Journal of Clinical Pharmacology;2024-03